Independent Predictors of Mortality in Polytrauma Patients

January 8, 2015 updated by: Luiz Guilherme Villares da Costa, University of Sao Paulo

Independent Predictors of Mortality in Polytrauma Patients: a Prospective, Observational, Longitudinal Study

Prospective observational trial searching for independent predictors of mortality. Data was collected at trauma scene, ER, three and 24 hours of hospital stay.The patients will be followed for 30 days after hospital admission.

Study Overview

Status

Completed

Conditions

Detailed Description

The study protocol was approved by the Institutional Medical Ethics Committee (CAPPesq 1081/09) and received financial support from the São Paulo State Research Foundation (Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP) under no. 2010/03315-4.

At the end of data prospecting, 334 patients with severe trauma (Injury Severity Score, ISS, >15), assisted by the rescue system and taken to HCFMUSP-Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo- (by land and helicopter) were included in the study. This screening strategy included trauma patients with severe confirmed bleeding, patients with severe traumatic brain injury (TBI) and patients facing high-energy trauma (a marked characteristic of this trauma center). Patients under 18 years of age were excluded ( Figure 1).

In total, 78 patients were excluded because they did not fit the above criteria, leaving 256 patients for analysis. Of this total, 34 patients died before arriving at the emergency room, and 22 were removed from the analysis due to incomplete data, not signing the informed consent form or due to any situation in which the data collection could compromise victim care(care Figure(Figure 1).

All patients had data recorded at the following times: 1, at the trauma scene; 2, in the emergency room; 3, at 3 hours after hospital admission; and 4, at 24 hours after hospitalization.

Data regarding gender, age, trauma and trauma mechanism, medical procedures performed at all stages, time until arrival at the hospital and comorbidities were recorded. The clinical data collected were as follows: systolic blood pressure (SBP); diastolic blood pressure (DBP); heart rate (HR); respiratory rate (RR); arterial hemoglobin oxygen saturation (SAT); Glasgow Coma Scale (GCS) score; and pupil pattern. The following laboratory data were collected through peripheral venipuncture at the hospital stages: pH(hydrogenic potential); base excess (BE); bicarbonate (BIC); partial oxygen pressure (pO2); partial carbon dioxide pressure (pCO2); arterial hemoglobin oxygen saturation; lactate; sodium (Na+); potassium (K+); ionized calcium (Ca2+); glucose; hemoglobin (Hb); hematocrit (Ht); serum creatine phosphokinase (CPK); platelets and leukocytes. Data regarding volume expansion [crystalloids (CRYSTAL), colloids (COLO)], diuresis and water balance were also collected. The use of blood products [packed red blood cells (PRBC), fresh frozen plasma (FFP), platelet concentrates (PLAT), cryoprecipitate concentrates (concentrates (CRYO)] was computed, and the use of vasoactive drugs (VAD) was scored at the respective times. Patient follow-up was conducted at the intensive care unit (ICU), and time of ICU stay (days in the ICU), days under mechanic ventilation (days under MV), the presence or absence of sepsis, coagulopathy and acute renal failure (ARF) were recorded.

Blood coagulation data were collected as follows: time point 1, International Normalized Ratio (INR) and prothrombin time (PT); and time points 2, 3 and 4, INR, PT, activated partial thromboplastin time (aPTT), the respective ratio between aPTT of patients and controls (R) and thrombin time (TT).

The following severity indexes were calculated: ISS, revised trauma score (RTS); trauma and injury severity score (TRISS); and simplified acute physiology score (SAPS) 3 (the latter when the patient was in the ICU).

At time point 1, blood tests were performed using the i-STAT® device (Abbott, USA; PT/INR and CG4+ and CG8+ kits). At the hospital stages, the analyses used the clinical analysis methodology of the HCFMUSP.

Clinical follow-up was conducted for 30 days after initial trauma.

Statistical analyses The sample power analysis was conducted with a significance level of 0.05, power of 0.80, moderate correlation of 0.5 between time periods and assumption that the variability is equal within each factor (non-sphericity). Due to the effect size between 0.1 and 0.5, there was no need for samples larger than 140 patients. A total of 200 patients waswere defined conservatively, with a margin for possible deaths. The software G*Power 3.1.7 was used for sample size calculation.

The data analysis was divided into three interconnected parts. The first part refers to the descriptive data analysis and tests of association with death. The second part addressed the profiles of the time-dependent measures and their relationship with death through analysis of nonparametric variance for repeated measures. The third part includes the set of all previous analyses that resulted in a Generalized Estimating Equation (GEE).

For the first part, the analyses were performed with the overall sample (n=200) subdivided into two groups: deaths (n=52) and non-deaths (n=148). For qualitative variables, the two-tailed Fisher's exact test was used, and for quantitative variables, the two-tailed t test or the two-tailed Mann-Whitney test was used according to the normality of the variable, which was verified by the Anderson-Darling test.

In the second part, the profiles of each measure over time were analyzed for groups of survivors and non-survivors. Nonparametric analyses of variance (NPar ANOVA) were conducted.

Finally, in the third part, a GEE model was developed considering the family of binomial distributions (dichotomous response variable) with logit link function. Only the main effects of each measure were considered. The NPar ANOVA (p>0.1) was the test used for inclusion in the model. The variables for the final models were selected using the backward method, with output alpha equal to 0.05. All part 3 results were interpreted by estimating odds ratios (OR), their corresponding 95% confidence intervals and significance tests (p-value).

The significance level was set at 0.05, and the free software R 3.0.2 was used for performing the statistical analyses.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • São Paulo, Brazil, 05403000
        • Instituto Central do Hospital das Clínicas da Universidade de São Paulo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Severe trauma patients evaluated at trauma scene

Description

Inclusion Criteria:

  • severe trauma (ISS - Injury Severity Score- >15)

Exclusion Criteria:

  • under 18 years old patient,
  • technical problems during rescue maneuvers,
  • impossibility of blood sample draw during rescue
  • informed consent not provided

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
severe trauma patients
analysis of blood samples and clinical features
clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death
Time Frame: Within the first 30 days
30 days after trauma mortality evaluation
Within the first 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Luiz G Costa, MD, Hospital das Clínicas da Universidade de São Paulo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (ACTUAL)

June 1, 2013

Study Completion (ACTUAL)

August 1, 2014

Study Registration Dates

First Submitted

August 8, 2012

First Submitted That Met QC Criteria

August 20, 2012

First Posted (ESTIMATE)

August 21, 2012

Study Record Updates

Last Update Posted (ESTIMATE)

January 9, 2015

Last Update Submitted That Met QC Criteria

January 8, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1081/09

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Trauma

Clinical Trials on analysis of blood samples and clinical features

3
Subscribe